Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Unilife Medical Solutions files a patent application for its Unifill Select ready-to-fill syringe

Unilife Medical Solutions Limited today announced the filing of patent applications in the United States ("US") for a new ready-to-fill syringe product to be marketed as the Unifill™ Select. Unilife is confident that this new pipeline product, which is to be primarily targeted for use with vaccines, can further expand the Company's ability to penetrate the pharmaceutical market for prefilled syringes.

25 Nov 2009

Myasthenia Gravis Alliance receives Global Pharmaceuticals grant to further research and awareness

Global Pharmaceuticals, the generic products division of Impax Laboratories, Inc., today announced their cooperation in awarding a modest grant to Myasthenia Gravis Alliance, also known as Myasthenia Gravis Foundation of Greater New York, Inc., a 501(3)(c) non profit membership corporation, incorporated in the State of New York.

25 Nov 2009

New biodegradable drug-eluting fibers advance stent technology and brain surgery

Stents that keep weakened and flabby arteries from collapsing have been true life-savers. But after six months, those stents are no longer needed -- once the arteries are strengthened, they become unnecessary. Previously, doctors had no choice but to leave them in place.

25 Nov 2009

Delcath Systems sponsors "Regional Therapeutic Options for Metastatic Melanoma" symposium

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, recently sponsored a Satellite Symposium at the World Meeting of Melanoma/Skin Cancer Centers in Berlin, Germany. The session, titled "Regional Therapeutic Options for Metastatic Melanoma," was held on Friday, November 20 and featured updates and observations on a variety of current therapies by clinical leaders in the field.

24 Nov 2009

A.P. Pharma regains compliance with shareholders’ equity requirement for continued listing on Nasdaq Capital Market

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 19, 2009, the Company received notice from the Nasdaq Listing Qualifications Panel that it has regained compliance with the shareholders’ equity requirement for continued listing on the Nasdaq Capital Market.

23 Nov 2009

Experts to discuss the patented chemical imaging technology at DDL 20 meeting

In today's fast growing inhalables market, the availability of suitable, efficient and cost-effective means of gathering particle analysis data for pulmonary formulation is clear. At this year's Drug Delivery to the Lungs 20 (DDL 20) meeting, experts from ChemImage Corporation, will be on hand to discuss our patented chemical imaging technology and how ingredient-specific particle sizing (ISPS) fulfils precisely this requirement for drug particle size data.

23 Nov 2009

Impax Laboratories implements IBM's business analytics technology

IBM announced today that Impax Laboratories, Inc., a technology-based specialty pharmaceutical company, is using IBM business analytics technology to gain stronger insights into their business and better predict risks and market opportunities.

20 Nov 2009

Soligenix receives $9.4M NIAID grant to develop technology for advancing rapidly acting vaccines

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has formed a consortium to develop thermostable technology to advance RiVax(TM) and other rapidly acting vaccines. Soligenix received a $9.4 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to support this work.

20 Nov 2009

BD acquires HandyLab for $275 million

BD today announced the completion of its acquisition of HandyLab, Inc., an Ann Arbor, Michigan-based company that develops and manufactures molecular diagnostic assays and automation platforms.

From BD (Becton, Dickinson and Company) 20 Nov 2009

NIEHS grants $13 million for engineered nanomaterials research

The National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health, is increasing its investment in understanding the potential health, safety and environmental issues related to tiny particles that are used in many everyday products such as sunscreens, cosmetics and electronics. The NIEHS will award about $13 million over a two-year period, through the American Recovery and Reinvestment Act, to bolster the NIEHS's ongoing research portfolio in the area of engineered nanomaterials (ENMs).

20 Nov 2009

Positive results from Echo Therapeutics' Symphony tCGM System study

Echo Therapeutics, Inc., a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, today announced positive results of a clinical study of its Symphony tCGM System in patients with Type 1 and Type 2 Diabetes.

19 Nov 2009

Recent progress of Delcath Systems in drug delivery platform reported

Delcath Systems, Inc., a medical technology company developing the Delcath Percutaneous Hepatic Perfusion (PHP(TM)) System, a minimally invasive drug delivery platform for the regional treatment of cancer metastatic to the liver, today reported on the Company's recent progress.

19 Nov 2009

World's first intra-arterial cerebral infusion of Avastin directly into a patient's malignant brain tumor

Neurosurgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center performed the world's first intra-arterial cerebral infusion of Avastin (bevacizumab) directly into a patient's malignant brain tumor. This novel intra-arterial (IA) technique may expose the cancer to higher doses of the drug therapy, while possibly sparing the patient common side effects of receiving the drug intravenously (IV) or throughout their body.

18 Nov 2009

Capsugel to have exclusive rights to Appian Labs' AppiForm Modular Release System technology

Appian Labs, LLC, a biopharmaceutical company specializing in advanced therapeutic design and delivery, has announced an exclusive Development and Commercial License Agreement for the company’s AppiForm™ Modular Release System with Capsugel, the world's leading provider of dosage form solutions to the pharmaceutical and related healthcare industries. The agreement provides for Capsugel to utilize the AppiForm Modular Release System for customizable drug delivery profiles.

17 Nov 2009

IntelGenx completes first successful human study of an anti-migraine film

IntelGenx Corp. is pleased to announce the results of a clinical pilot study that suggests IntelGenx has successfully developed a product that is bioequivalent to a leading branded anti-migraine therapy. The product (INT008) has been developed using IntelGenx's proprietary immediate release film "VersaFilm" drug delivery technology. VersaFilm provides a patent-protected method of formulating in a convenient and discrete dosage form.

17 Nov 2009

MEMS: Sensors made for automobiles are being used for healthcare devices

MEMS industry execs attending the annual MEMS Executive Congress last week were rapt by presentations and panel discussions by leading innovators in automotive, bio/medical, consumer electronics, mobile communications and energy. Buoyed by optimistic forecasts for microelectromechanical systems (MEMS) devices such as accelerometers and multi-axis gyros—increasingly used in mobile handsets and video games—they engaged with keynote speaker Dr. Mauro Ferrari, professor and director of The Division of NanoMedicine and Deputy Chairman of The University of Texas Department of Biomedical Engineering, whose proteomic NanoChips and multi-stage drug-delivery systems may one day ‘cure cancer.’

17 Nov 2009

BioSante Pharmaceuticals applauds Boehringer Ingelheim for developing a therapy to treat HSDD

BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company developing products for female sexual health, including LibiGel® for the treatment of hypoactive sexual desire disorder (HSDD), applauds the efforts of Boehringer Ingelheim to develop a therapy to treat this unmet medical need.

17 Nov 2009

A.P. Pharma announces financial results for its third quarter ended September 30, 2009

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2009.

16 Nov 2009

Researchers develop microscopic polymer beads to deliver antioxidant enzyme into heart

Researchers at Emory University and the Georgia Institute of Technology have developed microscopic polymer beads that can deliver an antioxidant enzyme made naturally by the body into the heart.

16 Nov 2009

Echo Therapeutics to raise $3 million from institutional investors

Echo Therapeutics, Inc., a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that it has entered into definitive agreements with accredited and institutional investors to raise approximately $3 million through the sale of approximately 2.37 million shares of common stock at $1.25 per share through a private placement transaction.

13 Nov 2009

Drug Delivery News and Research

Further Reading

Unilife Medical Solutions files a patent application for its Unifill Select ready-to-fill syringe

Myasthenia Gravis Alliance receives Global Pharmaceuticals grant to further research and awareness

New biodegradable drug-eluting fibers advance stent technology and brain surgery

Delcath Systems sponsors "Regional Therapeutic Options for Metastatic Melanoma" symposium

A.P. Pharma regains compliance with shareholders’ equity requirement for continued listing on Nasdaq Capital Market

Experts to discuss the patented chemical imaging technology at DDL 20 meeting

Impax Laboratories implements IBM's business analytics technology

Soligenix receives $9.4M NIAID grant to develop technology for advancing rapidly acting vaccines

BD acquires HandyLab for $275 million

NIEHS grants $13 million for engineered nanomaterials research

Positive results from Echo Therapeutics' Symphony tCGM System study

Recent progress of Delcath Systems in drug delivery platform reported

World's first intra-arterial cerebral infusion of Avastin directly into a patient's malignant brain tumor

Capsugel to have exclusive rights to Appian Labs' AppiForm Modular Release System technology

IntelGenx completes first successful human study of an anti-migraine film

MEMS: Sensors made for automobiles are being used for healthcare devices

BioSante Pharmaceuticals applauds Boehringer Ingelheim for developing a therapy to treat HSDD

A.P. Pharma announces financial results for its third quarter ended September 30, 2009

Researchers develop microscopic polymer beads to deliver antioxidant enzyme into heart

Echo Therapeutics to raise $3 million from institutional investors

Drug Discovery - Second Edition eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News